: Maintained its lead in prescription sales and remained a "Strong Buy" due to its robust clinical pipeline and steady dividend.

: Led the industry in R&D spending, focused heavily on its blockbuster immunotherapy Keytruda .

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec

: Gained over 700% after positive Phase 2 data for its epilepsy treatment, ganaxolone.

: Delivered a 516% return as it dominated its niche in the metabolic disease market.

In , the pharmaceutical sector outperformed the broader market, with the SPDR S&P Biotech ETF (XBI) surging approximately 40% , doubling the returns of the S&P 500 . This growth was fueled by significant FDA approvals and high-value partnerships between biotech startups and industry giants. 🚀 Top Performing Pharma & Biotech (2017)

For investors seeking stability and income, large-cap pharma stocks remained dominant through R&D investment and consistent payouts.

: Rose nearly 700% following a lucrative licensing deal with Novartis for its antibody gevokizumab.